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Background: A steady increase in HIV drug resistance 
(HIVDR) has been demonstrated globally in individuals 
initiating first-line antiretroviral therapy (ART). To sup-
port effective use of ART and prevent spread of HIVDR, 
monitoring is essential. Aim: We piloted a surveillance 
system for transmitted HIVDR to assess the feasibil-
ity of implementation at the European level. Method: 
All 31 countries in the European Union and European 
Economic Area were invited to retrospectively submit 
data on individuals newly diagnosed with HIV in 2015 
who were tested for antiviral susceptibility before 
ART, either as case-based or as aggregate data. We 
used the Stanford HIV database algorithm to trans-
late genetic sequences into levels of drug resistance. 
Results: Nine countries participated, with six report-
ing case-based data on 1,680 individuals and four 
reporting aggregated data on 1,402 cases. Sequence 
data were available for 1,417 cases: 14.5% of individu-
als (n = 244) showed resistance to at least one antiret-
roviral drug. In case-based surveillance, the highest 
levels of transmitted HIVDR were observed for non-
nucleoside reverse-transcriptase inhibitors (NNRTIs) 
with resistance detected in 8.6% (n = 145), followed 
by resistance to nucleoside reverse-transcriptase 
inhibitors (NRTI) (5.1%; n = 85) and protease inhibi-
tors (2.0%; n = 34). Conclusion: We conclude that 
standard reporting of HIVDR data was feasible in the 
participating countries. Legal barriers for data shar-
ing, consensus on definitions and standardisation of 
interpretation algorithms should be clarified in the 
process of enhancing European-wide HIV surveillance 
with drug resistance information.
Background
The global scale-up of antiretroviral treatment (ART) 
has led to considerable reductions in HIV-related 
morbidity and mortality. Increasing the proportion of 
patients who achieve viral suppression during treat-
ment will further reduce HIV transmission rates [1]. 
However, HIV drug resistance (HIVDR) poses a threat to 
the long-term success of ART and to the elimination of 
HIV/AIDS [2]. To address this issue, the World Health 
Organization (WHO) published a Global Action Plan 
on HIV Drug Resistance [3]. One of the five strategic 
objectives focuses on monitoring and surveillance to 
ensure access to the most effective drugs. Preventing 
and managing the occurrence of HIVDR is a key com-
ponent of a comprehensive and effective HIV response 
and should be integrated into broader efforts to ensure 
sustainability. It is essential that actions to monitor, 
prevent and respond to HIVDR are implemented at 
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clinical, programme and policy level, targeting the vari-
ous drivers of HIVDR.
At present, there is no European-level surveillance 
of HIVDR, although individual clinicians request 
sequence-based data in patients newly diagnosed with 
HIV before antiretroviral treatment initiation (or in case 
of treatment failure) to guide the choice of the first-line 
ART as recommended by the European AIDS Clinical 
Society [4]. Because of its impact on public health and 
clinical treatment guidelines, transmitted drug resist-
ance (TDR) is the primary focus of HIVDR surveillance at 
the European level, e.g. in the SPREAD project [5]. The 
prevalence of TDR is an important indicator to inform 
national and European Union (EU) guidance on therapy 
initiation for newly diagnosed HIV patients. Systematic 
HIVDR surveillance is the best tool to deliver timely and 
representative information on a regular basis. Such 
surveillance will also provide essential information on 
the most adequate pre- and post-exposure prophylaxis 
regimens and treatment in general.
A recent survey within the European HIV surveillance 
network revealed that some countries publish their 
national HIVDR data in surveillance reports or in sci-
entific publications [6]. However, it also indicated that 
countries use different methods to define and select 
study populations and this may complicate the inter-
pretation and comparison of national HIVDR preva-
lence data. International comparison of HIVDR results 
may also be hampered by different methods for the 
interpretation of drug resistance mutations. Although 
a number of EU countries have the technical and epi-
demiological capacity to monitor HIVDR, there is cur-
rently no common surveillance cycle, nor a common 
framework to interpret findings from HIVDR monitoring. 
Here, we describe a pilot study aimed at enhancing HIV 
surveillance with information on TDR and assessing its 
feasibility for implementation at the European level.
Methods
In September 2017, the European Centre for Disease 
Prevention and Control (ECDC) invited nationally 
appointed HIV experts from all 31 countries in the EU 
and European Economic Area (EEA) to participate in the 
pilot study. Countries were invited to participate if they 
had submitted epidemiological HIV surveillance data 
(year of diagnosis 2015) to The European Surveillance 
System (TESSy). We asked the countries to submit ret-
rospectively HIVDR data that were already available at 
the national level and to contribute to the development 
of a reporting protocol for the pilot surveillance sys-
tem. The reporting protocol specified three reporting 
options: (i) case-based data with HIV sequences, (ii) 
case-based data with mutation codes or drug resist-
ance interpretations, or (iii) aggregate data. Mutations 
codes were selected by the countries based on their 
own sequencing results. Reported additional variables 
included demographic, epidemiological and clinical 
data. Aggregate data were requested by sex (male/
female), transmission route and main drug class.
We defined the population of interest for the HIVDR 
surveillance pilot as ‘newly diagnosed treatment-naïve 
HIV patients tested before initiating HIV treatment for 
susceptibility to any of the 22 available antiretrovi-
ral (ARV) drugs in the four main drug classes’. In this 
study, we only collected information on diagnoses with 
HIV-1. In the context of this pilot study, pre-exposure 
prophylaxis (PrEP) was not considered treatment, but 
cases who at some point in time received PrEP were 
included. HIVDR was defined as any mutation or com-
bination of mutations that, according to the Stanford 
HIV drug resistance database (HIVdb) [7], results in 
low, intermediate or high-level resistance to currently 
available drug classes: non-nucleoside reverse tran-
scriptase inhibitor (NNRTI), nucleoside reverse tran-
scriptase inhibitor (NRTI), protease inhibitor (PI) and 
integrase inhibitor (INI).
Table 1
Number of records submitted per country, HIV drug resistance pilot surveillance, European Union, 2017 (n = 9 countries)
Country
Reported records for HIVDR pilot surveillance (year 2015) New HIV diagnoses in 2015 [15]
Case-based records Aggregate records Number of HIV diagnoses n % included in pilot
Belgium 472 1,001 47
Germany 618 3,674 17
Hungary 14 271 5
The Netherlands 277 802 35
Slovenia 15 48 31
Sweden 284 18 284 447 64
Denmark 64 118 277 43
France 0a 707 3,943 18
Ireland 15 293 486 60
Total 1,680 97 1,402 10,949 15
HIV: human immunodeficiency virus; HIVDR: HIV drug resistance;
a Data were excluded from analysis as submission was not according to the reporting protocol.
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In this pilot, the Stanford HIVdb version 8.4 algorithm 
was used, which defines the interpretation of the sub-
mitted sequences [7]. HIVdb is an expert web-interface 
system that accepts user-submitted HIV-1 sequences 
and returns inferred levels of resistance to 22 ARV 
drugs. HIVdb is regularly updated and new resistance 
patterns are included. The HIVdb system assigns a drug 
penalty score to each drug resistance mutation (DRM; 
consisting of an amino acid position number and the 
amino acid change from the wildtype to the mutation, 
e.g. V106I in the reverse transcriptase protein); for each 
sequence, the total score for a drug is derived by add-
ing the scores of each DRM associated with resistance 
to that drug. The programme reports one of the follow-
ing five levels of inferred drug resistance (defined as 
‘drug resistance interpretation’): susceptible, poten-
tial low-level resistance, low-level resistance, inter-
mediate resistance and high-level resistance. In this 
pilot, we considered ‘potential low-level resistance’ as 
‘susceptible’.
For specific selection of TDR, the Stanford database 
also presents a list of surveillance drug resistance 
mutations (SDRM list; mutation codes are available 
from [8]) that contains 93 mutations, including 34 NRTI-
resistance mutations at 15 reverse transcriptase (RT) 
gene positions, 19 NNRTI-resistance mutations at 10 
RT positions and 40 PI-resistance mutations at 18 pro-
tease gene positions [9,10]. This list does not include 
integrase resistance mutations.
Country representatives submitted data online, as 
comma-separated value files, to a secure data exchange 
platform (Voozanoo, EpiConcept) which ensured data 
security compliant with European standards for pro-
cessing health data. We checked the uploaded files 
manually for compliance with the correct format and 
merged the data into a single spreadsheet. We parsed 
text files with sequence data, linked to unique record 
identifiers, through the online Stanford HIVdb algo-
rithm and merged the output into the datasheet to 
allow comparison of drug resistance interpretation with 
the original submissions.
After data submission, we interviewed the national 
experts to assess the feasibility of reporting and to 
evaluate the pilot HIVDR surveillance system. The inter-
views aimed to understand the limitations, barriers and 
challenges that were encountered during data prepara-
tion and submission. Also, to assess the comparability 
of the data from different European countries, an esti-
mation of the national coverage of the HIVDR data was 
requested from the individual countries. Participants 
received the questionnaire in advance to prepare for 
the interviews. Individual summary reports with the 
information from the questionnaire and the interviews 
were validated by all countries.
Results
Data submission and overall prevalence of HIV 
drug resistance
Nine of 31 countries participated in the pilot study, six 
reported case-based data and four aggregated data 
(one country reported both).  Table 1  shows the data 
submission by country: 1,680 case-based records, 97 
aggregate data records, and two sets with aggregate 
data from France. The data submitted for this pilot 
represent a proportion of the total number of new HIV 
diagnoses in 2015 in the participating countries, rang-
ing from 5% in Hungary to 60% in Sweden and Ireland 
(Table 1). The completeness of reporting ranged from 
21% for integrase sequences to 100% for sex and prior 
ARV treatment.
The six countries that provided case-based surveil-
lance data also reported sequences: 1,417 records 
included one or more protease or reverse transcriptase 
sequences. Five countries submitted sequences for all 
individual records; Sweden provided sequences for TDR 
cases only. Table 2 presents the number of submitted 
sequences, the mutation codes (from Stanford HIVdb) 
and the overall observed TDR prevalence by country. 
France submitted only two sets with outcome tables 
presenting aggregated cases by sex and was therefore 
excluded from the analysis.
Table 2
Submitted sequences, mutation codes and proportion with transmitted drug resistance, case-based reporting, HIV drug 
resistance surveillance pilot, European Union, 2017 (n = 6 countries)
Country Records submitted Sequences submitted Any mutation code % TDR 95% CI
Belgium 472 472 74 15.7 12.5–19.3
Germany 618 618 114 18.4 15.5–21.7
Hungary 14 14 1 7.1 0.2–33.9
The Netherlands 277 277 34 12.3 8.7–16.7
Slovenia 15 15 0 0.0 0–21.8
Swedena 284 21 21 7.4 4.6–11.1
Total 1,680 1,417 244 14.5 12.9–16.3
CI: confidence interval; HIV: human immunodeficiency virus; TDR: transmitted drug resistance.
a Sweden only submitted sequences for TDR cases.
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Table 3  presents the overview of reported TDR in 
case-based surveillance (six countries) and aggregate 
surveillance (three countries). TDR in the case-based 
surveillance was calculated from reported resistance 
mutation codes and resistance interpretations, com-
bining low, intermediate and high resistance for each 
of the four drug classes. TDR in the aggregate surveil-
lance is as reported by the countries. The overall TDR 
was 14.5% among case-based surveillance and was 
higher than the 11.9% overall TDR reported in aggre-
gate format.
Congruence – methodological variations
Comparison of the reported resistance interpreta-
tion with the results of our sequence analysis showed 
an overall 98.8% congruence with a wide range of 
36–100% (data not shown). The lowest observed con-
gruence was among 11 cases with intermediate NNRTI 
resistance according to sequence analysis (36%).
Comparison of the reported mutation codes with the 
results of our sequence analysis showed high levels 
of congruence. For example, between 95% and 96% of 
the reported NRTI, NNRTI and PI mutation codes were 
identical to the mutation codes that we generated with 
the sequence analysis of the Stanford HIVdb algorithm 
(data not shown). However, in 32 (16%) of the 200 
records with reported mutation codes, the Stanford 
algorithm identified additional mutation codes.
Expert interviews
The national data source for HIVDR test results was 
the same as for the epidemiological HIV surveillance in 
Germany, Hungary, and the Netherlands. For the other 
six countries the data source was different because 
the HIVDR specimens and test results were mostly 
obtained through a collaboration between clinics or 
laboratories.
The sampling frame for HIVDR testing was comprehen-
sive for Belgium, France, Germany, Hungary, Ireland 
and Sweden, it was sentinel for Denmark and ‘other’ 
for the Netherlands and Slovenia. In the interviews, 
estimates for the national coverage of HIVDR sampling 
and testing ranged from 5% to 80% of the total popu-
lation of newly diagnosed HIV patients. All countries 
except France and Hungary stated that the test results 
were representative for the true TDR prevalence in their 
country. Countries considered the population captured 
in the HIV surveillance system representative for the 
national population of newly diagnosed HIV patients. 
France and Hungary did not describe all newly diag-
nosed patients that were tested for drug resistance and 
coverage was therefore too low to produce reliable TDR 
prevalence rates. All other countries argued that the 
sampling framework or the selected reference labora-
tories did not introduce bias towards certain sub-pop-
ulations or drug classes. However, it was noted that 
data for Ireland may include some cases of acquired 
drug resistance in patients who were newly diagnosed 
in Ireland but who may have been previously treated 
abroad.
The countries followed different internal procedures 
to organise and carry out the HIVDR testing: Denmark, 
Germany, Hungary, Ireland, Slovenia and Sweden 
reported that HIVDR testing was done at the central 
level, including the analyses and interpretation. In 
Belgium, France and the Netherlands, the HIVDR test 
results were collected and analysed at the central level, 
but the actual sequences were obtained from regional 
centres or laboratories.
The results of HIVDR testing could be linked to an 
individual HIV diagnosis in the epidemiological sur-
veillance in Belgium, Denmark, France, Hungary, the 
Netherlands and Slovenia. In most cases, this was 
Table 3
Number of cases (and proportion of tested) with mutations in newly diagnosed HIV cases, HIV drug resistance pilot 
surveillance, European Union, 2017 (n = 9 countries)
Drug class
Case-based surveillance 
 
(6 countries)
Aggregate surveillance 
 
(3 countries)
Total 
 
(combined for 9 countries)
n % n % n %
Total number tested 1,674 100 1,118 100 2,792 100
HIVDR any classa 244 14.6 133 11.9 377 13.5
NRTI 85 5.1 58 5.2 143 5.1
NNRTI 145 8.7 71 6.4 216 7.7
PI 34 2.0 31 2.8 64 2.3
INIb 10 2 12
DRM: drug resistance mutation; HIV: human immunodeficiency virus; HIVDR: HIV drug resistance; INI: integrase inhibitor; NRTI: nucleoside 
reverse transcriptase inhibitor; NNRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.
a At least one DRM reported as low, intermediate or high in any of the groups (NRTI, NNRTI, PI or INI).
b It is unknown how many individuals were tested for INI resistance, so no percentage is calculated.
This table displays number of cases; because six duplicates were reported, the number of cases is different from the number of records 
reported in Table 2, column ‘Records submitted’.
5www.eurosurveillance.org
done by a unique identifier requiring validation by the 
public health institute. In three countries, the link-
age was either explicitly forbidden by data protection 
and patient safety regulations (Sweden) or was under 
review (Germany and Ireland).
Discussion
This HIVDR surveillance pilot was a first study on the 
feasibility of setting up routine HIVDR monitoring in 
the EU/EEA. Results from the pilot suggest differences 
among the nine participating countries with respect to 
methodology (e.g. selection of population under sur-
veillance, type of resistance studied) and application 
of standards (e.g. use of mutation code, interpreta-
tion of the SDRM list vs sequence analysis using the 
Stanford HIVdb). As it is likely that signals of emerg-
ing or increasing HIVDR could start in a single country 
or in a specific sub-population, it is essential that all 
countries and sub-populations should be represented 
in future HIVDR surveillance. This was already the case 
for most countries participating in specific, EU-wide 
studies such as SPREAD [5]. Comparison of continuous 
data is key to detection of unusual signals and lack of 
harmonisation is a barrier for accurate comparison of 
data. We consider this a valid argument for EU-wide 
coordination and harmonisation of HIVDR monitoring.
A key question for future EU-wide HIVDR surveillance 
is whether data should be collected in case-based 
or aggregate format. Case-based surveillance that 
includes sequences would allow the greatest flexibil-
ity: it allows adjustment to future changes in resistance 
patterns and (re-)analysis of the data. Newly discov-
ered resistance mutations can be added to the analyti-
cal algorithm and applied to historical data, to allow 
a more reliable description of trends over time, with 
less risk of surveillance artefacts from re-classification 
of resistance mutations. This pilot study showed high 
levels of congruence: almost all sequence-detected 
mutations were also reported through the national 
interpretations. However, the sequences also provided 
additional relevant mutations. Standardised drug 
resistance interpretation among countries is crucial 
and surveillance using sequences will be more accu-
rate as it avoids coding errors that might occur in a 
system that collects mutation codes or interpretations 
derived from mutation codes.
From a conceptual point of view, we see in the above 
sufficient arguments in favour of an EU-coordinated 
HIVDR surveillance system that collects case-based 
data with sequences. However, there are considerable 
challenges for implementation of such a molecular sur-
veillance system at EU level. Technical issues identified 
in this pilot will need to be addressed. The semi-auto-
matic approach in this pilot identified a small number 
of sequences that could not be parsed and therefore 
a uniform quality assessment of sequence data would 
need to be applied before sequence submission.
Even though we believe that the technical solutions will 
not be trivial, such barriers may be overcome relatively 
easily. Patient confidentiality, data protection, data 
ownership and sharing issues on the other hand, were 
mentioned by all countries as major obstacles for sub-
mission of case-based data with sequences. Although 
the pilot demonstrated that countries were technically 
able to submit case-based data and sequences, not all 
had permission to do so as legal obstacles prevented 
the linking of molecular data and data submission. 
Among the countries that did submit sequences, most 
indicated that this could only be done for the pilot and 
that sequence data had to be destroyed at closure of 
the project. This was even mentioned for aggregated 
data sets. Furthermore, access to the sequence data 
by third parties must be controlled. The intended use 
of sequence data should be clearly defined and shar-
ing of sequence data should be restricted and based 
on signed agreements and surveillance protocols. 
Collection of aggregate data sets may reduce patient 
confidentiality and data protection issues, but it would 
be more difficult to analyse the data across countries. 
The pilot also showed that preparing aggregate data 
sets is error-prone. An alternative would be to collect 
only the mutation codes or resistance interpretations, 
provided that all countries would agree on common 
resistance interpretation rules and that countries agree 
to submit case-based data.
The overall TDR prevalence in this pilot (13.5%) was 
higher than previously reported for European coun-
tries [5]. This could be due to the use of different 
case definition, different methods for calculating and 
interpreting the resistance mutations or the use of dif-
ferent cut-off values for resistance, or it could reflect 
the true TDR prevalence in the participating countries. 
Feedback from participating countries on the observed 
higher TDR prevalence suggests that the difference 
was probably caused by using different definitions of 
resistance and including integrase resistance. Previous 
reports from most countries were based on the SDRM 
list, while we used the Stanford HIVdb algorithm for the 
analysis. The latter is regularly updated and includes 
polymorphisms which are not included in the SDRM 
list. Moreover, this pilot study was meant to test fea-
sibility of reporting, and results from the limited data 
collection may not be interpreted as the true EU preva-
lence. Representativeness of the surveillance data was 
assessed only in qualitative interviews with country 
representatives. If European HIVDR surveillance is con-
sidered in the future, then it is recommendable to per-
form a systematic assessment of representativeness of 
the data sources.
Belgium reported 9.9% overall TDR in 2015 [11] which is 
lower than the 15.7% in this pilot. This is most probably 
due to using the WHO SDRM list from 2009 [10] rather 
than the Stanford HIVdb list. The observed TDR preva-
lence in Germany and Sweden was higher than in previ-
ous reports [12,13]. However, recent data from Sweden 
showed results comparable to our findings [14]. In the 
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German data, discrepancy was found between reported 
resistance interpretation and calculated resistance 
level in 25 of the 114 cases, nine of which had integrase 
resistance only. However, even when discarding these 
25 observations, the overall TDR remained higher than 
expected (14.4%). This too may be explained by the 
fact that Germany used the 2009 SDRM list in previous 
HIVDR reports rather than Stanford HIVdb, which has 
the list of updated SDRM in use and therefore detects 
higher number of SDRMs than the WHO SDRM list from 
2009.
Conclusion
From a technical feasibility point of view, this surveil-
lance pilot study can be considered as a success. All 
nine participating countries could provide the required 
data, although not all in the required format. The data 
could be used to produce the surveillance tables as 
agreed in the reporting protocol. Most countries have 
the technical possibility of linking laboratory and epi-
demiological data; however, legal barriers for data 
sharing need to be clarified and agreement on a data 
collection protocol is required before routine HIV sur-
veillance in the EU/EEA can be enhanced with HIVDR 
information.
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